MAXCYTE, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M | -$18.2M |
| Operating expenses | $78.7M | $82.7M | $84.8M | $66.5M | $48.4M |
| Cost of revenue | $6.2M | $7.1M | $4.7M | $5.1M | $3.6M |
| Cash from operations | -$34.4M | -$27.6M | -$21.7M | -$14.8M | -$10.7M |
| Capital expenditure | $1.8M | $1.7M | $3.7M | $18.5M | $3.8M |
| Free cash flow | -$36.2M | -$29.3M | -$25.4M | -$33.3M | -$14.5M |
| Impairments | $3.6M | $0 | $0 | $0 | $0 |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M |
Shares outstanding 107.1M · Free float 78.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.